Literature DB >> 18351017

Recombinant AAV viral vectors serotype 1, 2, and 5 mediate differential gene transfer efficiency in rat striatal fetal grafts.

Alphonse Lubansu1, Laurence Abeloos, Olivier Bockstael, Enni Lehtonen, David Blum, Jacques Brotchi, Marc Levivier, Liliane Tenenbaum.   

Abstract

Intrastriatal grafts of fetal ganglionic eminences (GE) can reverse symptoms of striatal lesions in animal models of Huntington's disease. On the other hand, neurotrophic factors have been shown to protect host striatal neurons from ongoing degeneration. Neurotrophic gene transfer into GE prior to grafting could combine the benefits of striatal neuron replacement and in situ delivery of neurotrophic factors. Here we evaluate the potency of recombinant adeno-associated viruses (rAAV) as vectors for gene delivery into rat embryonic (E15) GE using the eGFP reporter gene under the control of the strong cytomegalovirus (CMV) promoter. We observed a very efficient expression of the eGFP reporter gene in organotypic cultures of GE infected with rAAV serotype 1 from 4 days until at least 4 weeks postinfection. In contrast, transduction was low and absent when using serotype 2 and serotype 5 rAAV, respectively. Two months after transplantation of rAAV2/1-infected embryonic GE in adult rat striatum, more than 20% of grafted cells expressed eGFP. The majority of transduced cells in the graft were neurons as indicated by colabeling of GFP-immunoreactive cells with the NeuN marker. Our study suggests that GE transduced by rAAV-serotype 1 vectors could be an interesting tool to mediate efficient expression of a gene coding a neurotrophic factor in Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18351017

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  3 in total

Review 1.  A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.

Authors:  Abdelwahed Chtarto; Olivier Bockstael; Terence Tshibangu; Olivier Dewitte; Marc Levivier; Liliane Tenenbaum
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

Review 2.  Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology.

Authors:  Alejandro Negrete; Robert M Kotin
Journal:  Brief Funct Genomic Proteomic       Date:  2008-07-16

Review 3.  Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms.

Authors:  Liliane Tenenbaum; Marie Humbert-Claude
Journal:  Front Neuroanat       Date:  2017-04-10       Impact factor: 3.856

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.